J&J’s Covid-19 vaccine offers protection against breakthrough infections
No evidence of a drop in protection against Covid-19-linked hospitalisation and ICU admissions was reported.
Country Risk Report Q4 2021 - Professional Services
Latest in
Country Risk Report Q4 2021 - Professional Services
Humanigen achieves target enrolment in Phase II/III Covid-19 therapy trial
The trial’s primary goal is the occurrence of invasive mechanical ventilation or mortality through day 29.
By
Gritstone reports positive data from initial arm of Covid-19 vaccine trial
In the trial, the vaccine was well-tolerated with favourable safety profile.
By
COVID-19 health concern continues to decline in November: Poll
The health concern over COVID-19 declined for the third consecutive month in November, shows the COVID-19 concern index, which is…
Pluristem reports topline results from Covid-19 therapy trial
The results were based on the analysis of 89 participants enrolled in two clinical studies conducted in the US, Europe…
CanSino’s vaccine shows 96% efficacy against severe Covid-19 in Phase III trial
The Convidecia vaccine had an overall efficacy of 63.7% 14 days following inoculation in trial subjects.
OPKO Health’s Rayaldee shows effectiveness for Covid-19 in trial
Boosting Vitamin D levels with Rayaldee caused an early resolution of Covid-19-linked respiratory symptoms.
Akston’s Covid-19 shot meets primary immunogenicity goals in trial
AKS-452 vaccine was well tolerated in the trial with safety and tolerability profile comparable with previous data.